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ABSTRACT
Objective: Vancomycin has been used worldwide due to empirical therapy against methicillin-resistant Staphylococcus aureus  infections. As a result 
a selective pressure that favors the outgrowth of vancomycin intermediate S. aureus clones will be created. This study was carried out to evaluate 
vancomycin resistance pattern of S. aureus in Jordan. 
Methods: A total of 1179 samples, including 566 (48%) from human and 613 (52%) from animals were examined for the presence of S. aureus using 
standard biochemical tests and polymerase chain reaction (PCR) amplification of coa gene. Resistance to antibiotics was determined by the  disk 
diffusion method. Methicillin resistance strains were tested for vancomycin resistance by minimal inhibitory concentration (MIC), E- test, and the 
results were confirmed by  amplification of van genes, and Pulsed-field gel electrophoresis (PFGE).
Results: The prevalence of S. aureus among human source was: 19.35%, 14%, and 8.8% for nasal, nail, and skin, respectively, and for animal sources 
27.3%, 5.51%, and 15.86% for milk, nasal, and meat, respectively. Four VISA strains (1.87%) were found to colonize human nares, nails, and skin with 
vancomycin MIC of 4-8 μg/ml. Van B resistance gene was detected and PFGE with SmaI-digested VISA genomic DNA revealed two different pulsotypes. 
Conclusion: This is believed to be the first report of VISA strains containing vanB gene isolated from a routine carriage survey. Effective screening 
directed to persons colonized with VISA should therefore be a priority.
Keywords: Staphylococcus aureus, Vancomycin intermediate Staphylococcus aureus, Pulsed-field gel electrophoresis, Polymerase chain reaction, VanB genes.
INTRODUCTION
Staphylococcus aureus is a common pathogen associated with serious 
community and hospital-acquired diseases and has for long been 
considered as a major problem of Public Health [1]. Both healthy people 
and those with underlying illness are at risk for diverse skin and soft 
tissue infections, endocarditis, osteomyelitis, meningitis, bacteremia, 
and pneumonia [2] with mortality rates ranging from 6% to 40% [3]. 
Several virulence factors implicated in the pathogenesis of S. aureus 
strains have been described in the literature [4] which is involved in 
tissue invasion of the host cells.
Increasing prevalence of methicillin-resistant S. aureus (MRSA) 
infections has led to the extensive use of vancomycin for treating 
these conditions. However, the overuse of this antibiotic has led to 
the emergence of S. aureus strains with reduced susceptibility to 
vancomycin. Hiramatsu et al. [5] from Japan were the first to report a 
clinical strain of MRSA with reduced susceptibility to vancomycin. It 
was due to decreased availability of the vancomycin for intracellular 
target molecules. As a consequence of the extensive use of vancomycin, 
a selective pressure was established that eventually resulted in the 
emergence of strains of S. aureus with a decreased susceptibility to 
vancomycin and other glycopeptides. The reports of vancomycin-
intermediate S. aureus (VISA) and vancomycin resistance (VRSA) have 
been increasing from various parts of the world [6].
The emergence of vancomycin resistance strains exhibits different 
mechanisms. Another than plasmid-mediated vancomycin resistance 
gene transfer from Enterococcal species to S. aureus [7], laboratory 
studies have demonstrated that resistant to vancomycin can be 
produced by a step pressure procedure [8]. However, interspecies 
transfer of resistant genes was thought not to be responsible for 
intermediate resistance to vancomycin in S. aureus [9]. Instead, VISA 
strains have been observed to have lower growth rates and thicker cell 
walls than fully susceptible strains. The increases in cell wall turnover 
will lead to an increase of non-cross-linked d-alanyl-d-alanine side 
chains; these chains are capable of binding vancomycin outside of 
the cell wall, making less vancomycin available for intracellular target 
molecules [10]. Nevertheless, some data in the literature raise the 
possibility that factors in the invading bacterium may also contribute. 
Examination of the vancomycin minimal inhibitory concentration 
(MIC) value of MRSA strains that were recovered from patients with 
failed therapy showed that therapeutic failure correlated significantly 
with the vancomycin MIC value of the strains, even when this antibiotic 
was not used for therapy [11]. These data suggest that the vancomycin 
susceptibility profile of MRSA strains correlates with some aspects of 
the invasive potential of the bacteria.
Since the first observation of VISA, there is a steady increase in the 
number of cases with VISA and VRSA. In our region, a report from Jordan 
has been published in which a case of VISA was reported in the year 2006 
by Bakri and coworkers in a patient with erythrodermic psoriasis with 
a persistent S. aureus bacteremia [12]. Another interesting report came 
from Oman on the treatment of infective endocarditis due to VISA [13]. 
Moreover, five strains of VISA were reported from North Lebanon by 
MIC dilution method [14]. While vancomycin is traditionally a first line 
and relatively effective antibiotic, its continued use is under question, as 
reports of resistance in S. aureus isolates are increasing. Detection of VISA 
is difficult in the laboratory, and special inquiries about susceptibility 
testing methods may be needed. In contrast to some reports of S. aureus 
isolates with uniform susceptibility to vancomycin [15], the importance 
of screening of MRSA isolates for VISA has repeatedly been emphasized. 
However, a survey of laboratories indicated that many did not use methods 
that can detect VISA strains [10]. Due to these strains appear to have 
developed from strains of MRSA instead of a single clone, they have often 
been missed by disk diffusion testing. Surveillance of patient populations, 
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especially in units where the probability of MRSA carriage and prolonged 
glycopeptide therapy is high, should be regularly done using vancomycin 
agar screening tests, E-test, and Hi Comb vancomycin MIC strips as per 
the criteria of the centers for disease control and prevention [9]. Recently, 
VISA and VSSA isolates are easily separated using Matrix-assisted laser 
desorption ionization time-of-flight mass spectrometry [16].
Although the acquired vancomycin-resistance determinants vanA, 
vanB, vanD, vanE, vanF, and vanG have been reported from VRSA, these 
resistance determinants have not previously been identified in cases 
with intermediate resistance [17]. However, one study showed the 
existing of vanA gene among nasal isolates [18]. VISA-infected patients 
had underlying illnesses, and their infections did not appear to respond 
well to conventional treatment. It is necessary to check the level of 
susceptibility of MRSA to vancomycin, especially when VISA exposed to 
appropriate selective step-up pressure; the strains will eventually take 
a resistant form. The main objective of the study was to evaluate the 
possible occurrence of VISA in human and animal isolates of MRSA and 




Nail, nasal, and skin samples were obtained from Al-Balqa’ Applied 
University students.
Nasal swabs
A total of 217 nasal specimens were obtained with sterile swabs after 
rotating 5 times around the inside of both nostrils while applying 
constant pressure. Nasal swabs were collected and stored in an ice box. 
The swabs were incubated into Tryptic Soy Broth (TSB) containing 7% 
NaCl for 24 hrs and then subcultured on mannitol salt agar (MSA) and 
incubated at 37°C for 24 hrs [19].
Nail swabs
A total of 217 nail specimens were obtained by swabbing the subungual 
space of the nails from the hands with sterile cotton swabs. Swabs were 
transferred to TSB containing 7% NaCl for 24 hrs and then subcultured 
on MSA, incubated at 37°C for 24 hrs [20].
Skin swabs
About 68 specimens were taken from two separate sites on the 
forehead and one site from one cheek. The swabs were incubated into 
TSB containing 7% NaCl. The isolates were subcultured on MSA and 
incubated at 37°C for 24 hrs.
Clinical samples
Different sources of clinical isolates (blood infection, urinary tract 
infection, abscess, and ear and eye infections, etc.) from four hospitals in 
Jordan (Al-Salt, Prince Hamza, Al-Basheer, and Al-Islami) were collected 
aseptically and transported directly to the laboratory [21]. The isolates 
then subcultured on MSA and BPA, and incubated at 37°C for 24-48 hrs. 
The suspected colonies maintained on Staphylococcal 110 media and 
were kept at 4°C for identification procedures.
Animal samples
Animal samples were collected from three central slaughterhouses 
in Jordan which represent the population of animals in Amman city 
(capital of Jordan). Animals were local, and imported (Romanian and 
Australian) including 207 sheep, 67 goats, and 16 cows. The age of the 
animals ranged from 1.5 to 3 years.
Raw meat
A total of 219 meat samples obtained from various muscle sites by 
collection of segments of the muscle of slaughtered animals. Samples 
were enriched in TSB containing 7% NaCl for 24-48 hrs of incubation at 
37°C. A portion of the enrichment cultures was then streaked on MSA 
and BPA and incubated at 37°C for 24-48 hrs. The suspected colonies 
were maintained on Staphylococcal 110 media and kept at 4°C for 
identification.
Nasal swabs
About 290 swabs were obtained from nares of the animals before 
slaughtering. Swabs were transferred to the TSB containing 7% NaCl. The 
isolates were subcultured on MSA and incubated at 37°C for 24 hrs [22].
Milk samples
About 33 raw milk samples were taken from sheep barn belonging to 
Al-Balqa’ Applied University. None of these animals were diagnosed 
with clinical mastitis and have normal mammary glands. Samples were 
collected into sterilized screw cap bottles as described previously [23]. 
1 milk sample (10-15 ml) was taken aseptically from each mammary 
gland after washing with water and cleaning the teats with 70% ethanol. 
Milk samples were cultured on TSB containing 7% NaCl and the isolates 
were subcultured on MSA and BPA, and incubated at 37°C for 24-48 hrs. 
The suspected colonies then maintained on Staphylococcal 110 media 
and were kept at 4°C for identification.
Biochemical tests
Isolates were examined by gram stain, catalase, coagulase, clumping 
factor and Protein A (BBL™ Staphyloslide Latex), mannitol fermentation, 
oxidase, hemolysin production using human and sheep RBCs, amylase, 
protease, sensitivity to acriflavine [24], tellurite reduction, and DNase 
test. S. aureus strain (ATCC 25923) was used as a positive control for all 
biochemical tests [25].
Molecular identification of the isolates
Extraction of DNA
Bacterial culture was grown overnight in nutrient broth, and 2 mL of 
the culture was centrifuged for 2 minutes. The pellet was resuspended 
in 567 µL of TE buffer to which 30 µL of 10% SDS and 3 µL of 
20 mg/mL proteinase K were added, mixed gently and incubated for 
1 hr at 37°C. Following this, 100 µL of 5 M NaCl was added and mixed 
thoroughly. After addition of 80 µL of 10% CTAB, 0.7 M NaCl solution 
and the tubes were incubated for 10 minutes at 65°C. An equal 
volume of phenol/chloroform/isoamyl alcohol (25:24:1) was added, 
mixed well and centrifuged at 10,000 rpm for 10 minutes. The upper 
aqueous phase was transferred to a new tube, and an equal volume 
of chloroform/isoamyl alcohol (24:1) was added and centrifuged at 
10,000 rpm for 10 minutes. The upper aqueous phase was transferred 
to a new tube and 0.8 volumes of isopropanol were added, mixed gently 
until the DNA was precipitated. The DNA was washed with 70% ethanol 
and resuspended in 50 µL TE buffer [26]. DNA quality was assessed by 
Spectrophotometric analysis (Thermoscientific Nanodrop 1000, USA) 
at the absorbance ratio of 260 and 280 nm.
Polymerase chain reaction (PCR) amplification
For identification of S. aureus, the primers (COAG2 and COAG3) 
(5ʹ-ACCACAAGGTACTGAATCAACG-3ʹ and 5ʹ-TGCTTTCGATTGTTCG 
ATGC-3ʹ) specific for the coa gene of S. aureus were used (Table 1). 
The reaction was prepared with 10 µL of extracted DNA (20 nm), 
1 µM of each primer, 200 µM dNTPs, 1 U of Taq DNA polymerase, 2 mm 
of MgCl2, and 4 µL of 10 X buffer - with a final volume of 40 µL. The 
program used consisted of 50 seconds at 95°C, 2 minutes at 55°C, and 
4 minutes at 72°C for 40 cycles [27]. The separation of the amplified 
products was carried out using 1% (w/v) agarose gel electrophoresis 
stained with 0.5 g.ml of ethidium bromide in TBE buffer, 70 volts for 
1 hr. UV transillumination was used for the visualization of the bands, 
and the size of the amplified fragments was determined by comparison 
with a molecular weight marker (1 kb plus DNA Ladder or 100 bp DNA 
Ladder).
Vancomycin susceptibility testing in S. aureus
Disc diffusion method
Plates of Muller-Hinton Agar were seeded by bacterial broth culture 
and incubated following introduction of the antibiotic disks at 37°C for 
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18 hr. The following discs were used; clindamycin (2 µg), erythromycin 
(15 µg), gentamycin (10 µg), methicillin (10 µg), penicillin (10 µg), 
amikacin (30 µg), cefoxitin (30 µg), novobiocin (50 µg), tetracycline 
(30 µg), vancomycin (30 µg), linezolid (30 µg), teicoplanin (30 µg), 
ciprofloxacin (5 µg), levofloxacin (5 µg), tobramycin (10 µg), and 
trimethoprim-sulfa (25 µg). Antibiotic resistance profile was 
determined according to the guidelines recommended by Clinical and 
Laboratory Standards Institute [28]. S. aureus standard strain ATCC 
29213 was used as reference strain for MRSA, VSSA, and Enterococcus 
faecalis ATCC 51299 was used as a positive control (VRE). Variable 
diameters of inhibition zone were recorded for different antibiotics.
MIC agar method
Agar dilution method was applied using different concentration of 
vancomycin. Briefly, gradient plates of Mueller-Hinton agar were 
prepared with vancomycin (0.5-128 µg/ml). Colony suspension 
of 0.5 McFarland was prepared in normal saline from 18 to 24 hrs 
agar plate culture. All strains were spotted onto gradient plates and 
incubated overnight at 35°C for any visible growth. S. aureus ATCC 
29213 was used as vancomycin susceptible controls and E. faecalis 
ATCC 51299 as vancomycin-resistant control. The lowest concentration 
of an antimicrobial agent that will inhibit the visible growth of a 
microorganism is known as the MIC. Vancomycin breakpoints were 
defined as follows susceptible at a vancomycin agar MIC of ≤2 µg/ml, 
intermediate at a vancomycin MIC of 4 to 8 µg/ml, and resistant at a 
vancomycin MIC of ≥16 µg/ml [28].
Vancomycin E-test
The conventional vancomycin E-test strips (bioMerieux, 
Durham, NC) were used which consists of a printed gradient 
concentrations of vancomycin from 0.015 to 256 µg/ml. Bacterial 
suspension was adjusted to 0.5 McFarland and plates were incubated 
for 24 hrs at 35°C. MICs were read by a direct observation, and the 
results were interpreted according to CLSI breakpoints [29].
PCR amplification of vanA, vanB, and vanC genes
Conventional PCR amplifications were performed with crude DNA 
using primer pairs specific for vancomycin resistance genes (Fig. 1). The 
PCR conditions were as previously described, except for the annealing 
temperatures, which varied from 58°C to 60°C depending on the 
van-specific primers used [30]. E. faecalis ATCC 51299 was used as a 
positive control.
Pulsed-field gel electrophoresis (PFGE)
PFGE was performed using the Gene Path strain typing system 
(Bio-Rad, Tokyo, Japan). According to Yoshida et al. [31], samples of 
150 µl from overnight cultures grown in 3 ml BHI broth were harvested 
by centrifugation at 12,000 g for 1 minute, resuspended in 150 µl cell 
suspension buffer and maintained at 55°C. Lysozyme/lysostaphin 
(0.15 mg, 6 µl) and 150 µl embedding agarose were added to this 
suspension, which then was poured into a plug mold. After setting for 
20 minutes at room temperature, the agarose plug was placed in 500 µl 
lysis buffer with 20 µl lysozyme/lysostaphin (0.5 mg) and incubated at 
37°C for 1 hr. The plugs were then washed in 1 ml 1× wash buffer and 
incubated at 50°C for 16-20 hrs in 500 µl proteinase K buffer containing 
20 µl (12 U) proteinase K. Six wash steps, each continued for 30 minutes, 
were performed using 1 ml of 1 X washing buffer, followed by another 
wash in 0.1 X washing buffer and a final wash in 500 µl SmaI buffer. 
After the plugs were placed in 300 µl SmaI buffer, 5 µl (25 U) SmaI 
enzyme was added and the plugs incubated at 25°C for 16-20 hrs. After 
restriction digestion, the plugs were electrophoresed in 1% agarose 
gels using parameters preprogramed with the GenePath system using 
CHEF-DRIII (Bio-Rad) for Staphylococcal species. The resulting profiles 
were visualized by staining with ethidium bromide. Electrophoretic 
patterns were analyzed, and strains were considered identical when 
they shared same number and sizes of fragments. The strains varied 
with only 2 or 3 bands were considered closely related [32]. S. aureus 
ATCC 25923 was used as a control.
RESULTS
Isolation of S. aureus
A total of 1179 samples including 566 (48.0%) obtained from human 
and 613 (51.9%) obtained from animal sources were used in the 
study. Gram staining, mannitol fermentation, catalase, coagulase, 
staphyloslide latex test, and thermonuclease were important 
phenotypic identifying markers of S. aureus. The overall prevalence of 
S. aureus was 143 (25.6%) and 71 (11.58%) isolated from human and 
animal sources, respectively (Table 2).
Biochemical characterization of S. aureus
In this study, we found that all S. aureus were positive for oxidase, 
catalase, coagulase, clumping factor and protein A, manitole 
fermentation, acriflavin resistance, amylase, and tellurite reduction. 
However, a variation in the phenotypic characteristics of S. aureus 
isolated from human and animal sources was appeared in beta 
hemolysis on blood agar supplemented with 8% (v/v) human and 
sheep blood, protease on 2% skim milk agar, and DNase on toluidine 
blue- DNA Agar (Fig. 1). Human isolates obtained from clinical, 
nasal, nail, and skin showed 100%, 95.2%, 87.1%, and 83.3% for 
β- hemolysin; 96.8%, 95.2%, 90.3%, and 83.2% for DNase; 95%, 
100%, 80.6%, and 66.7% for protease activity, respectively. On the 
other hand, animal isolates obtained from nasal, meat, and milk 
showed 81.25%, 89.1%, and 88.9% for β- hemolysin; 81.25%, 86.9%, 
Table 1: Primer pairs specific for vancomycin resistance gene
Number of base (mere) Primer name Primer sequence Melting temperature
25 VanA 5ʹ-ATGAATAGAATAAAAGTTGCAATAC-3ʹ 62°C  
21 VanA1 5ʹ-CCCTTTAACGCTAATACGAT-3ʹ 62°C
23 VanB 5ʹ-CCCGAATTTCAAATGATTGAAAA-3ʹ 59°C
18 VanB1 5ʹ-CGCCATCCTCCTGCAAAA-3ʹ 59°C
23 VanC 5ʹ-GCTGAAATATGAAGTAATGACCA-3ʹ 58°C
21 VanC1 5ʹ-CGGCATGGTGTTGAATTTCGTT-3ʹ 58°C
Fig. 1: Phenotypic characterization of Staphylococcus aureus 
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and 88.8% for DNase; 68.75, 80.5%, and 77.8% for protease activity, 
respectively.
Molecular identification
PCR amplification for S. aureus
The isolation of the genomic DNA from the bacterial isolates was the 
first step for the molecular study. The DNA that extracted from the 
suspected S. aureus isolates were subjected to PCR and loaded on 0.7% 
agarose gel electrophoresis and photographed under UV light. The size 
of coa gene specific for S. aureus gives PCR products that ranged from 
approximately 440 to approximately 915 bp when comparing to the 
DNA marker (Fig. 2).
Antibiotic susceptibility test
Disk diffusion assay
Disk diffusion assay was performed according to the protocol recommended 
by CLSI. All isolates showed variable sensitivity to the antibiotics that have 
been used (Tables 3 and 4). Multidrug resistance is defined as a complete 
resistance to 3 or more antimicrobial classes. A high percentage of MRSA 
was isolated from human as compared to animal sources (Fig. 3). All isolates 
proved to be susceptible to vancomycin by the disc diffusion method.
Vancomycin MIC test
Agar dilution technique was used to determine the lowest concentration 
of vancomycin that inhibits the growth of MRSA strains. The test was 
Table 2: Numbers and percentages of S. aureus isolated from human and animal sources
Source n (%) Sample sources Number of samples S. aureus n (% ) Total No. (%)
Nasal 217 42 (19.35) 
Human sources Nail 217 31 (14.28) 143 (25.26%)
566 (48) Clinical 64 64 (100)  
Skin 68 6 (8.82)  
Animal sources Milk 33 9 (27.27)  
613 (52) Nasal 290 16 (5.52) 71 (11.58)
Meat 290 46 (15.86)
Total 1179 214 (18.15) 
S. aureus: Staphylococcus aureus
Table 3: Antibiotic sensitivity test among S. aureus strains isolated from human sources
Type of antibiotics Nasal No. 42 (%) Nail No. 31 (%) Clinical No. 64 (%) Skin No. 6 (%)
S I R S I R S I R S I R
Clindamycin (2 µg) 73.1 23.1 3.85 87.5 0 12.5 83.6 1.36 1.36 66.7 0 33.3
Erythromycin (15 µg) 14.3  85.7 12.9 0 87.1 6.3 0 93.7 16.7 0 83.3
Gentamycin (10 µg) 92.3 0 7.69 100 0 0 5.47 0 94.5 33.3 0 66.7
Methicillin (10 µg) 9.5 0 90.5 6.5 0 93.5 6.3 0 93.7 0 0 100
Penicillin (10 µg) 7.69 0 92.3 6.25 0 93.75 10.9 0 89 16.7 0 83.3
Amikacin (30 µg) 97.6 0 2.4 100 0 0 98.4 0 1.6 100 0 0
Cefoxitin (30 µg) 9.5 0 90.5 9.7 0 90.3 9.4 4.6 86 0 0 100
Novbiocin (50 µg) 95.2 0 4.8 100 0 0 93.7 0 6.2 100 0 0
Tetracycline (30 µg) 84.6 0 15.4 75 6.25 18.75 65.7 1.36 32.8 100 0 0
Vancomycin (30 µg) 97.6 2.4 0 100 0 0 95.3 4.7 0 100 0 0
Linezolid (30 µg) 92.3 0 7.69 93.6 3.2 3.2 93.75 1.6 4.7 83.3 16.6 0
Teicoplanin (30 µg) 71.4 4.8 23.8 87.1 0 12.9 78.2 3.1 18.7 83.3 0 16.7
Ciprofloxacin (5 µg) 85.7 0 14.3 93.5 0 6.5 43.8 0 56.2 66.6 16.7 16.7
Levofloxacin (5 µg) 7.1 2.4 90.5 16.1 0 83.9 1.6 1.6 96.8 50 0 50
Tobramycin (10 µg) 4.8 0 95.2 100 0 0 3.2 3.2 9.4 100 0 0
Trimethoprim (25 µg) 11.9 4.8 83.3 12.9 3.2 83.8 46.9 0 53.1 50 0 50
Table 4: Antibiotic sensitivity test among S. aureus strains isolated from animal sources
Types of antibiotics Nasal No. 16 (%) Meat No. 46 (%) Milk No. 9 (%)
S I R S I R S I R
Clindamycin (2 µg) 46.6 33.3 20 73.17 12.19 14.63 50 0 50
Erythromycin (15 µg) 18.7 0 81.3 13.1 0 86.9 0 0 100
Gentamycin (10 µg) 86.6 13.3 0 97.56 0 2.43 50 0 50
Methicillin (10 µg) 18.7 0 81.3 13.1 0 86.9 11.1 0 88.9
Penicillin (10 µg) 13.3 0 86.6 12.19 0 87.8 25 0 75
Amikacin (30 µg ) 93.7 0 6.3 82.6 0 17.4 88.9 0 11.1
Cefoxitin (30 µg) 93.7 0 6.3 95.6 0 4.4 33.3 0 66.7
Novbiocin (50 µg) 100 0 0 86.9 2.1 11 100 0 0
Tetracycline (30 µg) 66.6 20 13.3 31.7 17.07 51.21 66.7 0 33.3
Vancomycin (30 µg ) 100 0 0 100 0 0 100 0 0
Linezolid (30ug) 87.5 0 12.5 86.9 2.1 10.9 55.5 11.1 33.3
Teicoplanin (30 µg) 78.5 0 12.5 97.8 2.8 0 88.9 0 11.1
Ciprofloxacin (5 µg) 93.7 0 6.3 95.6 0 4.4 100 0 0
Levofloxacin ( 5 µg) 93.7 0 6.3 91.4 4.3 4.3 100 0 0
Tobramycin (10 µg) 81.2 0 18.8 86.9 0 13.1 88.9 0 11.1
Trimethoprim (25 µg) 37.4 6.2 62.6 87.8 9.75 2.43 55.6 0 44.4
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judged by the naked eye, disregarding a single colony or a thin haze 
within the area of the inoculated spot (Fig. 4). According to CLSI 
recommendations, four MRSA (1.87%) exhibits vancomycin MIC of 
4-8 µg/ml. These isolates belong to human (2.79%) and include 2 nasal 
(4.76%), 1 nail (3.2%), and 1 skin isolates (16.6%) (Table 5).
E-test
To confirm the presence of VISA detected by agar dilution MIC test, a 
standard E-test was performed. The concentration of vancomycin in the 
strips ranged from 0.015 to 256 µg/ml. The four VISA isolates found to be 
resistant to 4-8 μg/ml vancomycin by E-test (Fig. 5). VISA strains appeared 
resistant to oxacillin (100%), erythromycin (75%), and trimethoprim-sulfa 
(25%), while sensitive to other antibiotics that have been used (Table 6).
Detection of the van genes
The vancomycin-resistant genes - including vanA, vanB, vanC - were 
detected using a PCR as previously described. The PCR cycle was as 
follows: 1 cycle of 5 minutes at 94°C, then 35 cycles of 94°C, 1 minute, 
58°C, 1 minute, and 72°C 1 minute; followed by a final 10 minutes 
extension at 72°C. vanB gene was found in the four isolates of S. aureus 
with intermediate resistance to vancomycin (Fig. 6).
PFGE
Molecular analysis of SmaI-digested DNA resulted in two distinct PFGE 
types (Fig. 7) which confirmed their epidemiologic relationship. Isolates 
in lines 1, 3, and 4 showed the same profile (profile I) and isolates in line 
2 was considered different (profile II).
Fig. 2: Primer COAG 2, 3 for identification of Staphylococcus 
aureus, M: 100 bp marker ladder; P: Positive control of 
Staphylococcus aureus (440-915); samples from (2-22), (25-27), 
and (29-35) are Staphylococcus aureus; N: Negative control
Fig. 3: Percentages of methicillin-resistant Staphylococcus aureus 
among human and animal isolates
Fig. 4: Growth of Staphylococcus aureus on MHA containing 
4 µg/ml vancomycin
Fig. 6: Agarose gel electrophoresis of PCR- amplified vanB 
resistance gene. Lane M: 100 bp marker ladder; P: Positive 
control of VRE ATCC51299; samples 1,2,3, and 4 are vancomycin 
intermediate Staphylococcus aureus isolates; N: Negative control
Fig. 7: Pulsed field gel electrophoresis of vancomycin 
intermediate Staphylococcus aureus isolates digested with SmaI. 
Lane M:  Lambda ladder; Lane P: Positive control Staphylococcus 
aureus ATCC 25923; Lane 1: Nail isolate; Lane 2: Skin isolate; 
Lane 3, 4: Nasal isolate
Fig. 5: E-test for vancomycin intermediate Staphylococcus aureus 
(VISA) strains (a) VISA strain with MIC 4 µg/ml, and (b) VISA 
strain with MIC 8 µg/ml
ba
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DISCUSSION
S. aureus is recognized as a cause of a wide range of infections, from 
minor skin infections and chronic bone infections to devastating 
septicemia and endocarditis [33]. The accurate identification of 
Staphylococcus species impacts directly on treatment outcomes and 
on the epidemiological analysis. Due to the excessive and uncontrolled 
use of antibiotics the organism becomes multidrug resistant leaving 
few therapeutic options for the treatment against it. Knowledge of 
selection of the antibiotics for treatment is important as antibiotic 
responsiveness pattern of MRSA may vary from region to region. In this 
study, a total of 214 isolates (18.15%) were identified as S. aureus. The 
prevalence of S. aureus among human was 19.35% for the nasal, 14% 
for nail, and 8.8% for skin. These results are in agreement with results 
obtained by other researchers [34,35]. Strains present in the nose often 
contaminate the back of hands, fingers and face and so nasal carriers 
can easily become skin carriers [36]. However, animal sources showed 
27.3%, 5.51%, and 15.86% for milk, nasal, and meat, respectively. 
The biochemical tests that have been used for the primary isolation 
of S. aureus showed similar behavior concerning catalase, oxidase, 
coagulase, tellurite reduction, amylase, and resistance to acriflavine. 
However, human isolates showed an increase in their beta hemolytic 
activity, DNase, and protease production. These results are in agreement 
with Roberson et al., 1992 results. S. aureus that expresses large 
amounts of hemolysin, lipase, and DNase may be expected to colonize 
the skin and cause furuncles [37]. On the other hand, the prevalence of 
S. aureus in the meat samples could be indicative of contamination of 
meat from skin, mouth, and nose of butchers [38]. Although Samples 
of milk was obtained from sheep without any clinical mastitis and have 
normal mammary glands, the presence of S. aureus in milk samples was 
estimated to be 8%. This might be associated with subclinical mastitis 
and intramammary infection [39]. Isolates of S. aureus were confirmed 
by PCR analysis using coa gene primers.
MRSA infections can be very serious and are among the most frequently 
occurring of all antibiotic-resistant threats [40]. Our results showed 
that the majority of MRSA strains are associated with human isolates. 
This finding is supported by Boucher and Corey results, 2008. Increased 
prevalence of infection due to MRSA led to the use of glycopeptides 
for therapeutic purpose. The widespread use of vancomycin to treat 
infections has led to the emergence of vancomycin resistance strains. 
VISA appears to have developed from strains of MRSA instead of a 
single clone, and they have often been missed by disk diffusion testing. 
Such failures are widely under-reported, since most of the laboratories 
in the past would have considered these strains as vancomycin sensitive 
leading to failure with the use of antimicrobials for staphylococcal 
disease. Acceptable methods used to detect these strains are MIC of 
vancomycin and the E-test [41].
This study showed clearly the existent of VISA colonizing human nose, 
nails, and skin (4.76%, 3.2%, and 16.6%, respectively). Vancomycin 
MICs for the isolated strains ranged from 4 to 8 µg/ml. However, none 
of the students carrying VISA strains were on vancomycin at the time 
of survey. In a previous report from Jordan, a case of VISA was reported 
by Bakri et al. in a patient with erythrodermic psoriasis [12]. However, 
VISA has been reported from different parts of the world in which 
most of the reported cases were isolated from clinical samples [42]. 
In a study concerning nasal carriage survey for MRSA, four strains 
were detected with reduced susceptibility to vancomycin [18]. The 
isolation of VISA from nail, nasal, and skin colonization was rare, but 
the abused of vancomycin in our region at certain time might enhanced 
the presence of such strains. VISA colonizing normal human niches may 
be a potent source of VRSA, especially when exposed to the appropriate 
selective step-up pressure; these isolates may eventually take a 
resistant form. In addition, they may act as carriers, promoting easy 
transfer of drug resistance determinants. However, the complicated 
point is the potential for emergence of VRSA isolates from these strains 
during asymptomatic colonization, rather than during infection, which 
also might contribute to delays in the detection process [43]. Improper 
dosage and inadequate duration of therapy are other common causes 
in our country. Surveillance of populations, especially where the 
probability of MRSA carriage and prolonged glycopeptide therapy is 
high, should be regularly done by continuous monitoring of MIC levels 
of vancomycin.
The genetic changes that lead to the manifestation of the VISA 
phenotypes are varied and not easily detectible using a single gene 
assay. While these genetic alterations are variable, they tend to occur 
in regulatory genes that control cell metabolism and cell wall structure 
and function. Consequently, most VISA isolates share common 
phenotypic features such as increased cell wall thickness and slowed 
growth rate [44]. Increased cell wall thickness helps in resistance by 
sequestering vancomycin molecules in the cell wall peptidoglycan, thus 
reducing the susceptibility of S. aureus to vancomycin [10]. In this kind 
of cell wall structure, glycopeptides are confiscated and prevented from 
reaching the site of cell division. As a result, the rate of vancomycin 
diffusion decreases [45]. Another mechanism was identical to that seen 
in vancomycin-resistant Enterococcus faecium that harbors the vanA 
operon which contains 5 genes [46]. To determine the mechanism of 
acquirement of reduced vancomycin susceptibility of VISA strains, we 
detected the Van gene which was implicated in generation of vancomycin 
resistance [47]. S. aureus could acquire vancomycin resistance by 
transferring van genes which were even accomplished in the laboratory. 
However, none of the VISA strains appeared in previous studies showed 
to express any of the van determinants (vanA, vanB, vanC1, vanC2, 
or vanC3) present in VRSA [48]. In one interesting study from India 
including a nasal carriage survey for MRSA in an intensive care unit, 
Table 6: Antimicrobial resistance pattern of VISA strains 
isolated from human specimens
Type of antibiotics Skin Nasal Nasal Nail
Clindamycin (10 µg) S S S S
Erythromycin (15 µg) S R R R
Levofloxacin (5 µg) S S S S
Methicillin (5 µg) R R R R
Penicillin (10 µg) S S S S
Trimethoprim (25 µg) R S S S
Teichoplanin (30 µg) S S S S
Ciprofloxacin (5 µg) S S S S
Amikacin (30 µg) S S S S
Gentamycin (10 µg) S S S S
Cefoxitin (30 µg) R R R R
Novbiocin (50 µg) S S S S
Tetracycline (30 µg) S S S S
Vancomycin (30 µg) S S S S
Linezolid (30 ug) S S S S
Tobramycin (10 µg) S S S S
Gentamycin (10 µg) S S S S
VISA: Vancomycin intermediate S. aureus












Nasal (42) 40/02/00 1 (2.38%) 1 (2.38)
Nail (31) 30/01/00 - 1 (3.2%)
Skin (6) 05/01/00 - 1 (16.6)




Nasal (16) 16/00/00 - -
Meat (46) 46/00/00 - -
Milk (9) 09/00/00 - -
VISA: Vancomycin intermediate S. aureus
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four strains with reduced susceptibility to vancomycin were reported 
with vanA gene [18]. To the best of our knowledge, this is the first 
report of VISA strains containing vanB isolated from a routine carriage 
survey worldwide. Resistance to vancomycin could be acquired by 
transferring van genes in vivo. This transfer was detected in the absence 
of any antibiotic pressure [49]. The absence of a selective vancomycin 
pressure might have resulted in reduced expression of the vanB 
resistance gene. It was well known that vanB-type strains have variable 
levels of inducible resistance to low-level vancomycin but are sensitive 
to teicoplanin [50]. It was indicated that recurrent MRSA infection and 
certain underlying illnesses might increase the risk of development of 
VISA [51]. It seemed that, in this case, the serious underlying illness and 
high chance of exposure to MRSA colonization might also contribute to 
VISA infection. We next examined the susceptibilities of the VISA strains 
to other antibiotics clinically used to treat MRSA infection. We found 
that the strains with intermediate resistance to vancomycin were not 
associated with a multidrug-resistant phenotype.
PFGE of SmaI restriction fragment was used as a molecular typing 
technique for classification and epidemiologic survey of VISA. However, 
two different cluster patterns were obtained. The first cluster included 
isolates obtained from nasal and nail suggesting that they are closely 
related. The second cluster carries different bands and present isolate 
obtained from skin. Although both clusters contained vanB gene, 
they had different antimicrobial susceptibility patterns. Cluster I was 
resistance to cefoxitin and erythromycin, whereas Cluster II showed 
resistance to cefoxitin and trimethoprim. VISA strains isolated in 
this study may be a potent source of VRSA with the expression of the 
vancomycin resistance gene. Infections due to VISA is a recipe for a full 
blown development into VRSA if no proper measures are put in place to 
control their spread.
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